Tasly Pharmaceutical Adjusts Valuation Amid Declining Sales and Profit Challenges

Tasly Pharmaceutical Group Co., Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company's valuation score has been revised, reflecting a shift in its financial metrics and market position. Currently, Tasly's P/E ratio stands at 22, while its Price to Book Value is recorded at 1.64. The company’s EV to EBIT and EV to EBITDA ratios are noted at 14.41 and 11.46, respectively, indicating its operational efficiency relative to its earnings. Additionally, the EV to Capital Employed ratio is 1.71, and the EV to Sales ratio is 2.36. The dividend yield is reported at 2.22%, with a Return on Capital Employed (ROCE) of 11.90% and a Return on Equity (ROE) of 7.63%. Despite these metrics, the company has faced challenges in long-term growth, with net sales declining at an annual rate of -9.48% and operating profit decreasing by -2.22% over the past five years. Recent financial results have also shown a significant drop in net profit and operating cash flow. For more insights on Tasly Pharmaceutical Group Co., Ltd. and its financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.